The companys lead product candidate, LN-144, is a ready-to-infuse autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TIL) for the treatment of patients with metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and the H. Lee Moffitt Cancer Center & Research Institute. For more information, please visit lionbio.
Posted on: Tue, 06 Jan 2015 06:46:33 +0000
Trending Topics
Recently Viewed Topics
© 2015